Intellectual Thoughts by Sanjay Panda: Cipla to acquire US generic business

Cipla to acquire US generic business

Cipla has acquired two US-based generic drug companies -- InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc for a total value of $550 M.

InvaGen & Exelan Pharmaceuticals    owned by the promoter of Hyderabad-based drug maker Hetero Drugs Ltd.  InvaGen acquisition  provides Cipla with an access to large wholesalers/retailers in the US. While, the acquisition of Exelan Pharmaceuticals provides Cipla access to the government and institutional market in the US . The combined revenue  of these  two companies  were approx  $200 M in 2014.  

InvaGen Pharmaceuticals is not linked directly to the flagship companies of Hetero group, Hetero  likely to  continue to strengthen its  US  presence  by investing  in  its subsidiary firm Camber Pharmaceuticals Inc.

No comments: